ACE insertion/deletion, but not -240A> T polymorphism, modulates the severity in heart failure

Journal of Investigative Medicine

Volumn 56, Issue 8, 2008, Pages 1004-1010

  Fatini, Cinzia ^b   Sticchi, Elena ^b   Marcucci, Rossella ^b   Said, Abdihakim Abdullahi ^b   Del Pace, Stefano ^b   Verdiani, Valerio ^b   Nozzoli, Carlo ^b   Gensini, Gian Franco ^a,b   Abbate, Rosanna ^b  

^a IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

ACE I D and 240A>T gene polymorphisms; Heart failure; NYHA functional class

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76); UNCLASSIFIED DRUG;

AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CARDIAC PATIENT; DISEASE CLASSIFICATION; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENOTYPE; HEART FAILURE; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREVALENCE; SURVIVOR; ADULT; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED;

ADULT; AGED; FEMALE; GENE DELETION; GENOTYPE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC;

EID: 58149332369     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/JIM.0b013e31818e8028     Document Type: Article

References (26)

1. Dostal DE, Baker KM. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res. 1999;85:643-650.
2. Hirsch AT, Talsness CE, Schunkert H, et al. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res. 1991;69: 475-482.
3. Studer R, Reinecke H, Muller B, et al. Increased angiotensin-I converting enzyme gene expression in the failing human heart. Quantification by competitive RNA polymerase chain reaction. J Clin Invest. 1994;94: 301-310.
4. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/ deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343-1346.
5. Hamdi HK, Castellon R. A genetic variant of ACE increases cell survival: a new paradigm for biology and disease. Biochem Biophys Res Commun. 2004;318: 187-191.
6. Suehiro T, Morita T, Inoue M, et al. Increased amount of the angiotensin-converting enzyme (ACE) mRNA originating from the ACE allele with deletion. Hum Genet. 2004;115:91-96.
7. Foy CA, Rice GI, Ossei-Gerning N, et al. Angiotensin-converting enzyme (ACE) gene polymorphisms in patients characterised by coronary angiography. Hum Genet. 1997;100:420-425.
8. Schut AF, Bleumink GS, Stricker BH, et al. Angiotensin converting enzyme insertion/deletion polymorphism and the risk of heart failure in hypertensive subjects. Eur Heart J. 2004;25:2143-2148.
9. Andersson B, Sylven C. The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure. J Am Coll Cardiol. 1996;28:162-167.
10. Palmer BR, Pilbrow AP, Yandle TG, et al. Angiotensin-converting enzyme gene polymorphism interacts with left ventricular ejection fraction and brain natriuretic peptide levels to predict mortality after myocardial infarction. J Am Coll Cardiol. 2003;41:729-736.
11. McKee PA, Castelli WP, McNamara PM, et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;258:1441-1446.
12. Cifkova R, Erdine S, Fagard R, et al. Practice guidelines for primary care physicians: 2003 ESH/ESC Hypertension guidelines. ESH/ESC hypertension guidelines committee. J Hypertens. 2003;21:1779-1786.
13. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adult (Adult Treatment Panel III) final report. Circulation. 2002;106: 3143-3421.
14. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26:S5-S20.
15. Rigat B, Hubert C, Corvol P, et al. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypepti-dase 1). Nucleic Acids Res. 1992;20:1433.
16. Fatini C, Abbate R, Pepe G, et al. Searching for a better assessment of the individual coronary risk profile. The role of angiotensin-converting enzyme, angiotensin II type 1 receptor and angiotensinogen gene polymorphisms. Eur Heart J. 2000;21:633-638.
17. Ogimoto A, Hamada M, Nakura J, et al. Relation between angiotensin-converting enzyme II genotype and atrial fibrillation in Japanese patients with hypertrophic cardio-myopathy. J Hum Genet. 2002;47:184-189.
18. Gharavi AG, Lipkowitz MB, Diamond JA, et al. Deletion polymorphism of the angiotensin-converting enzyme gene is independently associated with left ventricular mass and geometric remodelling in systemic hypertension. Am J Cardiol. 1996;77:1315-1319.
19. Yano M, Kim S, Izumi Y, et al. Differential activation of cardiac c-jun amino-terminal kinase and extracellular signal-regulated kinase in angiotensin II-mediated hypertension. Circ Res. 1998;83:752-760.
20. Kajstura J, Cigola E, Malhotra A, et al. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol. 1997;29:859-870.
21. Wiese S, Breyer T, Dragu A, et al. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length. Circulation. 2000;102:3074-3079.
22. Cuoco MA, Pereira AC, de Freitas HF, et al. Angiotensin-converting enzyme gene deletion polymorphism modulation of onset of symptoms and survival rate of patients with heart failure. Int J Cardiol. 2005;99:97-103.
23. Braunwald E. ACE inhibitors - a cornerstone of the treatment of heart failure. N Engl J Med. 1991;325:351-353.
24. McNamara DM, Holubkov R, Postava L, et al. Pharma-cogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol. 2004;44:2019-2026.
25. Young JB, Dunlap ME, Pfeffer MA, et al. Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation. 2004;110: 2618-2626.
26. Fatini C, Sticchi E, Gensini F, et al. Lone and secondary nonvalvular atrial fibrillation: role of a genetic susceptibility. Int J Cardiol. 2007;120:59-65.